Beyond company-specific pipeline moves, the feed highlighted U.S. policy momentum around pricing transparency and federal priorities tied to clinical development. A separate report said the Trump administration will develop a system for health insurers to disclose prescription drug prices, with a final plan targeted by next May. In parallel, the market digested late-breaking clinical readouts, including a Phase 3 lymphoma win for Epkinly and a Phase 3 failure for furmonertinib, both of which can quickly re-shape near-term competitive positioning and payer conversations. Together, these items point to a near-term biotech environment where clinical outcomes and reimbursement signals are moving at the same pace as capital availability.